Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt

Hepatol Int. 2018 Jul;12(4):291-293. doi: 10.1007/s12072-018-9883-9. Epub 2018 Jul 10.

Authors

Tatsuo Kanda¹, Shunichi Matsuoka², Mitsuhiko Moriyama²

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan. kanda.tatsuo@nihon-u.ac.jp.
² Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.

PMID: 29992512
DOI: 10.1007/s12072-018-9883-9

No abstract available

Keywords: DAA; Genotype 4; HCV; SVR; Thyroid-stimulating hormone.

Publication types

Editorial

MeSH terms

Antiviral Agents* / administration & dosage
Antiviral Agents* / adverse effects
Antiviral Agents* / classification
Drug Therapy, Combination / methods
Egypt / epidemiology
Hepacivirus / drug effects
Hepacivirus / genetics
Hepatitis C, Chronic* / diagnosis
Hepatitis C, Chronic* / drug therapy
Hepatitis C, Chronic* / epidemiology
Hepatitis C, Chronic* / virology
Humans
Interferons / administration & dosage
Interferons / adverse effects
Liver* / metabolism
Liver* / pathology
Liver* / physiopathology
Sustained Virologic Response
Thyroid Gland* / drug effects
Thyroid Gland* / physiopathology
Treatment Outcome

Substances

Antiviral Agents
Interferons